METTL3-mediated m6A methylation of C1qA regulates the Rituximab resistance of diffuse large B-cell lymphoma cells
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
METTL3-mediated m6A methylation of C1qA regulates the Rituximab resistance of diffuse large B-cell lymphoma cells
Authors
Keywords
-
Journal
Cell Death Discovery
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-01
DOI
10.1038/s41420-023-01698-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis
- (2023) Michael Constantinides et al. Cancers
- Retracted: METTL3 enhances the effect of YTHDF1 on NEDD1 mRNA stability by m6A modification in diffuse large B‐cell lymphoma cells
- (2023) Lili Feng et al. Immunity Inflammation and Disease
- The role of m6A RNA methylation in cancer metabolism
- (2022) Yuanyuan An et al. Molecular Cancer
- Complement System: An Immunotherapy Target in Colorectal Cancer
- (2022) Iman M. Talaat et al. Frontiers in Immunology
- METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer
- (2022) Weijun Wan et al. Molecular Cancer
- m6A binding protein YTHDF2 in cancer
- (2022) Xiaomin Chen et al. Experimental Hematology & Oncology
- MORTALIN-Ca2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma
- (2022) Qi Sun et al. CANCER LETTERS
- Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma
- (2022) Young Wha Koh et al. Frontiers in Oncology
- The emerging roles of RNA m6A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance
- (2021) Qing Lan et al. CANCER RESEARCH
- Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer
- (2021) Jacob Gadwa et al. Journal for ImmunoTherapy of Cancer
- Complement C1q (C1qA, C1qB, and C1qC) May Be a Potential Prognostic Factor and an Index of Tumor Microenvironment Remodeling in Osteosarcoma
- (2021) Long-hao Chen et al. Frontiers in Oncology
- Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages
- (2021) Samantha B Kemp et al. Life Science Alliance
- Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance
- (2021) Bashir Lawal et al. Cancers
- The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation
- (2020) Tao Liu et al. NUCLEIC ACIDS RESEARCH
- Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth
- (2020) Sarah Davidson et al. Cell Reports
- The m6A Methyltransferase METTL3 Is Functionally Implicated in DLBCL Development by Regulating m6A Modification in PEDF
- (2020) Yingying Cheng et al. Frontiers in Genetics
- Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
- (2020) Wenxi Zhou et al. BIOMATERIALS
- m6A methyltransferase Wilms' tumor 1‐associated protein facilitates cell proliferation and cisplatin resistance in NK /T cell lymphoma by regulating dual‐specificity phosphatases 6 expression via m6A RNA methylation
- (2020) HongYan Ma et al. IUBMB LIFE
- The role of m6A RNA methylation in cancer
- (2019) Ting Sun et al. BIOMEDICINE & PHARMACOTHERAPY
- Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia
- (2019) Jasmin Paris et al. Cell Stem Cell
- Complement system's role in cancer and its therapeutic potential in ovarian cancer
- (2018) H. Bareke et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- The role of the complement system in cancer
- (2017) Vahid Afshar-Kharghan JOURNAL OF CLINICAL INVESTIGATION
- Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue
- (2015) T.A.M. Bouwens et al. JOURNAL OF NEUROIMMUNOLOGY
- Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
- (2014) P Macor et al. LEUKEMIA
- Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
- (2012) Xuan Jin et al. Journal of Hematology & Oncology
- Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
- (2012) Leticia Corrales et al. JOURNAL OF IMMUNOLOGY
- Rituximab resistance
- (2011) Andrew R. Rezvani et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
- (2008) E. Racila et al. CLINICAL CANCER RESEARCH
- The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
- (2008) X. Zhou et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now